Published in:
Open Access
01-12-2014 | Research article
Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study
Authors:
Lionel Piroth, André Pechinot, Vincent Di Martino, Yves Hansmann, Alain Putot, Isabelle Patry, Tahar Hadou, Benoit Jaulhac, Catherine Chirouze, Christian Rabaud, Alain Lozniewski, Catherine Neuwirth, Pascal Chavanet, Anne Minello
Published in:
BMC Infectious Diseases
|
Issue 1/2014
Login to get access
Abstract
Background
Current recommendations for empirical antimicrobial therapy in spontaneous bacterial peritonitis (SBP) are based on quite old trials. Since microbial epidemiology and the management of patients have changed, whether these recommendations are still appropriate must be confirmed.
Methods
An observational study that exhaustively collected the clinical and biological data associated with positive ascitic fluid cultures was conducted in four French university hospitals in 2010–2011.
Results
Two hundred and sixty-eight documented positive cultures were observed in 190 cirrhotic patients (median age 61.5 years, 58.5% Child score C). Of these, 57 were classified as confirmed SBP and 140 as confirmed bacterascites. The predominant flora was Gram-positive cocci, whatever the situation (SBP, bacterascites, nosocomial/health-care related or not). Enteroccocci (27.7% E. faecium) were isolated in 24% of the episodes, and in 48% from patients receiving quinolone prophylaxis. E. coli were susceptible to amoxicillin-clavulanate and to third-generation cephalosporins in 62.5% and 89.5% of cases, respectively. No single antibiotic allowed antimicrobial coverage of more than 60%. Only combinations such as amoxicillin + third-generation cephalosporin or cotrimoxazole allowed coverage close to 75-80% in non-nosocomial episodes. Combinations based on broader spectrum antibiotics should be considered for empirical therapy of nosocomial infections.
Conclusions
Our study confirmed the changing spectrum of pathogens in SBP and bacterascites, and the need for more complex antibiotic strategies than those previously recommended. Our findings also underline the need for new clinical trials conducted in the current epidemiological context.